High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation

Table 3 Risk factors for developing de novo donor-specific antibodies after liver transplantation.

Variable	Univariate analyses			Multivariate analyses
	OR	95%CI	P value	OR	95%CI	P value
MELD score > 30 (n = 31)	1.84	0.43-7.10	0.33	-
Initial liver disease
(1) Alcohol cirrhosis (n = 49) vs (2, 3, 4)	0.58	0.12-2.22	0.55	-
(2) Viral disease (n = 36) vs (1, 3, 4)	0.98	0.21-3.86	1.0	-
(3) Autoimmune ILD (n = 13) vs (1, 2, 4)	1.51	0.14-8.46	0.64	-
(4) Other (n = 18) vs (1, 2, 3)	2.79	0.55-11.83	0.64	-
Induction therapy, yes (n = 87)	1.61	0.41-7.61	0.55	-
Polyclonal antibodies (vs other)	0.59	0.70-18.00	0.60	-
IL2R blockers (vs other)	1.1	0.28-5.28	1.0	-
Donors’ age > 50 yr (n = 69)	0.78	0.20-3.00	0.77	-
Recipients’ age > 50 yr (n = 92)	0.36	0.09-1.58	0.10	0.2	0.07-0.85	0.3
HCV RNA + at transplantation (n = 21)	1.41	0.23-6.23	0.70	-
Steroid withdrawal during the FU (n = 19)	0.39	0.01-3.01	0.69	-
Tacrolimus trough level < 5 ng/mL (n = 34)	1.59	0.38-6.05	0.52	-
CV-IPV tacrolimus (continuous variable)	1.92	-1.28-21.39	0.08	1.1	1.0-1.12	0.006
CV-IPV > 35%	4.66	1.22-19.82	0.02	4.83	1.39-16.72	0.01
CV-IPV > 40%	9.10	2.28-40.63	< 0.001	9.73	2.65-35.76	0.001
CV-C0/d-IPV	3.15	5.47-27.31	0.005	1.0	0.97-1.02	0.09

FU: Follow-up; ILD: Initial liver disease; HCV: Hepatitis C virus; CV-IPV: Coefficient of variability-intra-patient variability; CV-C₀/d-IPV: Coefficient of variability corrected for the corresponding daily dose-intra-patient variability.